ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans

Journal of Clinical Pharmacology

Volumn 49, Issue 1, 2009, Pages 63-71

  Zhu, Tong ^a,c   Awni, Walid M ^a   Hosmane, Balakrishna ^b   Kelly, Maureen T ^a   Sleep, Darryl J ^a   Stolzenbach, James C ^a   Wan, Katty ^a   Chira, Titus O ^a   Pradhan, Rajendra S ^a  

^a ABBOTT LABORATORIES   (United States)

^b NORTHERN ILLINOIS UNIVERSITY   (United States)

^c Bldg AP13A 3 ^*  (United States)

Author keywords

Dyslipidemia; Fenofibric acid; Fibrate; Rosuvastatin

Indexed keywords

FENOFIBRATE; ROSUVASTATIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HUMAN; MALE; MULTIPLE DRUG DOSE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; STOMACH DISCOMFORT; VITAL SIGN;

ADULT; ANTILIPEMIC AGENTS; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; FLUOROBENZENES; HUMANS; MALE; MIDDLE AGED; PROCETOFEN; PYRIMIDINES; SULFONAMIDES; YOUNG ADULT;

EID: 58149181570     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008325671     Document Type: Article

References (31)

1. McGovern ME Taking aim at HDL-C. Postgraduate Med. 2005 ; 117: 29-44.
2. Wilt TJ, Bloomfield HE, MacDonald R., et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med. 2004 ; 164: 1427-1436.
3. National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the NCEP expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002 ; 106: 3143-3421.
4. Sattar N., Gaw A., Scherbakova O., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003 ; 108: 414-419.
5. Ford E., Giles WH, Dietz WH Prevalence of the metabolic syndrome among U.S. adults, findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002 ; 287: 356-359.
6. Crestor (rosuvastatin calcium) [prescribing information]. Wilmington, DE: AstraZeneca ; 2007.
7. Neuvonen PJ, Niemi M., Backman JT Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 ; 80: 565-581.
8. Brown CDA, Windass A., Bleasby K., Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C [abstract]. Atherosclerosis. 2001 ; 2: 90.
9. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2004 ; 75: 455-463.
10. Windass AS, Lowes S., Wang Y., Brown CDA. The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 ; 322: 1221-1227.
11. Zhang W., Yu BN, He YJ, et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta. 2006 ; 373: 99-103.
12. Huang LY, Wang Y., Grimm S. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistant protein. Drug Metab Dispos. 2006 ; 34: 738-742.
13. Kyrklund C., Backman JT, Neuvonen M., Neuvonen PJ Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther. 2003 ; 73: 538-544.
14. Backman JT, Kyrklund C., Kivistö KT, Wang J. -S, Neuvonen PJ Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther. 2000 ; 68: 122-129.
15. Kyrklund C., Backman JT, Kivistö KT, Neuvonen M., Laitila J., Neuvonen PJ Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther. 2001 ; 69: 340-345.
16. Backman JT, Luurila H., Neuvonen M., Neuvonen PJ Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther. 2005 ; 78: 154-167.
17. Backman JT, Kyrklund C., Neuvonen M., Neuvonen PJ Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther. 2002 ; 72: 685-691.
18. Martin PD, Dane AL, Schneck DW, Warwick MJ An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther. 2003 ; 25: 459-471.
19. Gustavson LE, Schweitzer SM, Koehne-Voss S., et al. The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3α-hydroxy isomeric metabolite. J Clin Pharmacol. 2005 ; 45: 947-953.
20. Pan W.-J., Gustavson LE, Achari R., et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol. 2000 ; 40: 316-323.
21. Bergman AJ, Murphy G., Burke J., et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol. 2004 ; 44: 1054-1062.
22. TriCor tablets [US prescribing information]. Abbott Park, IL: Abbott Laboratories ; 2005.
23. Medical Dictionary for Regulatory Activities. Reston, VA: MedDRA MSSO VAR1/8A/MSSO.
24. Jones PH, Davidson MH, Kashyap ML, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. National Lipid Association (NLA) Abstract 214. J Clin Lipidol. 2008 ; 2: 218.
25. Prueksaritanont T., Tang C., Qiu Y., Mu L., Subramanian R., Lin JH Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 2002 ; 30: 1280-1287.
26. Prueksaritanont T., Zhao JJ, Ma B., et al. Mechanistic studies in metabolic interactions between gemfibrozil and statins. J Clin Pharmco Exp Ther. 2002 ; 301: 1042-1051.
27. Lee E., Ryan S., Birmingham B., et al. Rosuvastatin pharmacokinetcs and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005 ; 78: 330-341.
28. Tzeng T., Mitchell P., Zhang H., Kung L., Schneck D., Birmingham B. Population pharmacokinetics of rosuvastatin in normal subjects and subjects with dyslipidemia [abstract]. Clin Pharmacol Ther. 2004 ; 75: 56.
29. Sekino H., Onishi T. Phase I study of ZD4522 (rosuvastatin), a new HMG-CoA reductase inhibitor evaluation of tolerance and pharmacokinetics in healthy adult male volunteers after single and repeated oral administration. J Clin Ther Med. 2005 ; 21: 187-203.
30. Warwick MJ, Dane AL, Raza A., Schneck DW Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522 [abstract]. Atherosclerosis. 2000 ; 151: 39.
31. Martin PD, Mitchell PD, Schneck DW Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol. 2002 ; 54: 472-477.